Replay available

Bactiguard Holding AB (publ) (BACTI_B) Q3 2025 Earnings Call

Bactiguard Holding AB (publ) (STO: BACTI_B) Q3 2025 earnings conference call, held 2025-10-23. Replay captured from the company's public earnings webcast.

Thu, October 23, 2025 at 5:00 AMendedReplay
Bactiguard Holding AB (publ) (BACTI_B) Q3 2025 Earnings Call

Hosted by

Featured presenters

Patrick Bock

CFO

Matthias Vadsten

Analyst, SEB

Christine Lind

CEO

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Bactiguard Holding Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.795 Welcome to the BactiGuard Q3 2025 report presentation. 00:00:04.795 -- 00:00:09.199 For the first part of the conference call, the participants will be in listen-only mode. 00:00:09.199 -- 00:00:14.144 During the questions and answers session, participants are able to ask questions by dialing 00:00:14.144 -- 00:00:19.749 pound key 5 on their telephone keypad. Now I will hand the conference over to the speakers, 00:00:19.749 -- 00:00:25.612 CEO Christine Lind and CFO Patrick Bock. Please go ahead. 00:00:26.975 -- 00:00:31.312 Thank you, operator. and welcome to the presentation of Back to Guard's report for the 00:00:31.312 -- 00:00:33.894 third quarter of 2025. 00:00:33.894 -- 00:00:38.079 Our CFO, Patrick Buck, and I will go through the presentation together, and we will have 00:00:38.079 -- 00:00:41.881 a Q&A session towards the end. 00:00:43.165 -- 00:00:46.949 Let's start with some high-level comments on the quarter, and Patrick will go into more 00:00:46.949 -- 00:00:50.391 financial details later in the presentation. 00:00:50.833 -- 00:00:56.647 We have had another profitable quarter with EBITDA totaling 5.3 million SEC, 00:00:56.647 -- 00:01:01.434 And the investments we have made over the last two years in strengthening the organization 00:01:01.434 -- 00:01:08.184 and capabilities to support licensing have not jeopardized our margins or impacted profitability. 00:01:08.184 -- 00:01:13.292 Even though we do not yet demonstrate significant top-line growth, we deliver a strong 00:01:13.292 -- 00:01:18.460 EBITDA, and I am confident that we are equipped to execute on the opportunities for 00:01:18.460 -- 00:01:24.895 our infection prevention technology across our strategic therapeutic areas. 00:01:24.895 -- 00:01:30.224 Total ...